Drug intelligence / Profile preview

Viusid + Asbrip

Development stage: Unknown
Lead developer: Catalysis
Modality: Small Molecules
Administration: Oral

Overview

Viusid + Asbrip is a combination therapy consisting of two dietary supplements developed by Catalysis S.L. Viusid is an antioxidant and immunomodulating supplement containing glycyrrhizinic acid, glucosamine, amino acids, and vitamins, designed to support the immune system and mitigate inflammatory responses. Asbrip is a supplement containing activated molecular components such as eucalyptus and mint, intended to alleviate respiratory symptoms like cough and congestion. The combination has been investigated in clinical trials for the treatment of mild to moderate COVID-19 symptoms, aiming to reduce viral hyperinflammation and improve clinical outcomes through antioxidant and symptomatic support.

Other names: Viusid + Asbrip

Targets

HMGB1 (High mobility group protein B1)

Beyond the preview

Go deeper on Viusid + Asbrip.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Viusid + Asbrip.

Explore the full profile